Key Data Looms Soon – This Small-Cap Stock Could Be the Biggest Dark Horse in the GLP-1 Market
💬 GLP-1 investors: Tired of only giants dominating the weight-loss space? Think small-cap biotechs can still deliver 10-bagger returns? Which under-the-radar name is on your watchlist?
While global drugmakers flood into the GLP-1 sector, and giants build deep moats with tens of billions in annual revenue, one small biotech company with a $4 billion market cap is quietly approaching its “moment of truth.”
$Viking Therapeutics(VKTX)$ has no approved products yet, but its core pipeline drug VK2735 is hitting a critical inflection point. The company plans to release clinical data for the drug as a maintenance dose in the third quarter of this year.
If the results are positive, this small-to-mid-sized biotech could see a short-term price surge and carve out meaningful market share from giants Novo Nordisk and Eli Lilly.
A Binary Gamble
Viking’s situation is widely known among investors as a “binary bet” — if VK2735 succeeds, the stock could skyrocket; if it fails, the price will likely crash back to baseline.
This sharp high-risk, high-reward profile defines the biotech stock’s core appeal.
The injectable version of VK2735 is already in Phase 3 trials, and a Phase 3 study for the oral formulation is scheduled to launch before year-end.
Even more notably, Viking is exploring the drug’s potential as a maintenance treatment — patients don’t have to restart therapy from scratch, but instead switch to VK2735 for long-term weight management after achieving significant weight loss.
If this strategy proves viable, it could drastically widen its addressable market.
Unlike many early-stage biotechs with distant catalysts, Viking’s catalysts are coming month by month.
Based on “exciting early data,” the company has launched studies evaluating VK2735 as a maintenance dose, covering monthly injectable formulations and daily/weekly oral options.
The results expected in Q3 will mark the first critical milestone validating this game-changing strategy.
Acquisition Appeal Before a $100B+ Pie
The GLP-1 market has explosive long-term prospects. Industry forecasts widely predict global annual sales of related drugs will hit $100 billion by around 2030, with the rise of oral formulations as a key growth driver.
Against this backdrop, Viking’s small size becomes a major advantage.
With a market cap of only about $4 billion, it stands in stark contrast to the trillion-dollar valuations of Novo and Lilly — making it a high-value, attractive acquisition target for large pharmaceutical companies.
Analysts believe if follow-up data for VK2735 remains consistently positive, Viking could receive a premium buyout offer. A bid at 3x current valuation is far from unrealistic.
The stock once traded near $100 per share; today, it hovers at only around $32.
Buy the Dip or Wait?
Since 2026, Viking’s stock has dropped 6%, and it’s down 24% from its 52-week high.
The company is not yet profitable, posting a $360 million net loss last year, with nearly all hopes riding on VK2735.
This is a classic “all-or-nothing” investment — any setback in clinical data could trigger extreme volatility.
For investors with strong risk tolerance, the current window could be a quiet setup before the dust settles.
In the crowded but still red-hot GLP-1 space, small-cap names with differentiation potential are rare.
Viking is using its “make-or-break moment” to secure a ticket to the massive weight-loss market.
No matter the outcome, this under-the-radar dark horse will face its “truth moment” this third quarter.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
